### Supplement 1. Baseline Characteristics and Oncologic Treatments in CCS of different Childhood Cancer Diagnoses

The CCS cohort (n=57) consisted of 23 (40%) patients with leukemia (acute lymphoblastic leukemia and acute myeloid leukemia), 19 patients (33%) with lymphomas (Hodgkin’s lymphoma and non-Hodgkin’s lymphoma), 10 patients with Wilms tumor (18%) and 5 patients (9%) with sarcomas (Ewing’s sarcoma, osteosarcoma and rhabdomyosarcoma). The median cumulative anthracycline (AC) dose was 186.50 mg/m2 (range 0-471.25 mg/m2), and five patients did not receive any anthracyclines (all patients with Wilms tumor). The most common pharmacologic agents besides AC were vincristine (n=51, 89%), steroid therapy (n=36, 63%), cyclophosphamide (n=30, 52%), methotrexate (26, 45%), cytarabine (n=25, 43%), iphosphamide (n=22, 38%) and etoposide (n=17, 29%). Twenty-three patients (4%) had been treated with radiotherapy of which 10 with mediastinal- (17%), 8 with cranial- (14%) and 5 with other (abdominal and extremity) radiotherapy (9%).

#### S1.Table 1 Treatments in the Childhood Cancer Survivor Group

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Diagnosis | Total n=57 | Leukemia, n=23 | Lymphoma, n=19 | Wilms, n=10 | Sarcoma, n=5 |
| Age (y) | 25.02 (22.01-30.04) | 26.04 (22.02-30.04) | 24.10 (22.09-29.60) | 25.08 (22.01-29.04) | 23.53 (22.11-28.04) |
| Sex (females, %) | 23 (40.4%) | 8 (34.8%) | 7 (36.8%) | 5 (50.0%) | 3 (60.0%) |
| Anthracyclines (n, %) | 52 (91.2%) | 23 (100.0%) | 19 (100.0%) | 5 (50.0%) | 5 (100.0%) |
| Cum Anthracyclines (mg/m2) | 186.5 (0-471.3) | 219.6 (120-446) | 160 (97-471.3) | 25 (0-200) | 293.4 (197-302) |
| Cyclophosphamide (n, %) | 30 (52.6%) | 11 (47.8%) | 16 (84.2%) | 2 (20.0%) | 1 (20.0%) |
| Iphosphamide (n,%) | | | 22 (38.6%) | 10 (43.5%) | 8 (42.1%) | 0 (0.0%) | 4 (80.0%) |
| Steroid Therapy (n, %) | 36 (63.2%) | 20 (87.0%) | 15 (79.0%) | 0 (0.0%) | 1 (20.0%) |
| Methotrexate (n,%) | 26 (45.6%) | 21 (91.3%) | 5 (26.3%) | 0 (0.0%) | 0 (0.0%) |
| Dactinomycin (n,%) | 14 (24.6%) | 0 (0.0%) | 0 (0.0%) | 10 (90.0%) | 5 (100.0%) |
| Cytarabine (n,%) | 25 (43.9%) | 20 (87.0%) | 5 (26.3%) | 0 (0.0%) | 0 (0.0%) |
| Etoposide (n,%) | 17 (29.8%) | 10 (17.5%) | 13 (68.4%) | 0 (0.0%) | 4 (80.0%) |
| Bleomycin (n,%) | 1 (1.8%) | 0 (0.0%) | 1 (5.3%) | 0 (0.0%) | 0 (0.0%) |
| Triazenes (n,%) | 11 (10.5%) | 0 (0.0%) | 11 (31.6%) | 0 (0.0%) | 0 (0.0%) |
| Carmustine (n,%) | 2 (3.5%) | 0 (0.0%) | 2 (10.5%) | 0 (0.0%) | 0 (0.0%) |
| Platinum Agents (n,%) | 3 (3.5%) | 0 (0.0%) | 0 (0.0%) | 2 (20.0%) | 1 (20.0%) |
| Vinca Alkaloids (n,%) | | 51 (89.5%) | 23 (100.0%) | 16 (79.0%) | 10(100.0%) | 5 (100.0%) |
| Radiotherapy (y/n) | 24 (42.1%) | 8 (31.6%) | 9 (47.4%) | 4 (40.0%) | 3 (60.%) |
| Mediastinal Radiotherapy (n,%) | 10 (17.5%) | 0 (0.0%) | 9 (47.4%) | 1 (10.0%) | 0 (0.0%) |
| Cranial Radiotherapy (n,%) | 8 (14.0%) | 8 (31.6%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Other (n,%) | 6 (10.5%) | 0 (0.0%) | 0 (0.0%) | 3 (30.0%) | 3 (60.0%) |

**Supplement 1.** Different treatments in the different diagnosis groups. Age and the cumulative anthracycline dose are shown as median (range). Other variables are shown as number (n) and %. **Abbreviation:** Cum – cumulative.